RCT Exudate Management Cutimed Sorbion Product Range

Official title

A Prospective, Multicenter, Partially Assessor Blinded, Randomised, Open Label, Parallel, Comparative Clinical Trial to Evaluate the Exudate Management Performance of Cutimed Sorbion Product Range

Overview

The fluid handling capacity of superabsorbent dressings varies depending on the design and construction. The use of effective advanced wound dressings is a promising strategy to achieve adequate absorption of wound exudate and malodour promoting wound healing. The aim of the current study is to determine whether there is a difference in the clinical performance of exudate absorption with two commonly used CE-marked superabsorbent dressings when used on VLUs in routine wound care. As primary objective the dressing´s absorption performance and its ability to prevent skin maceration and leakage of the wound dressing will be investigated.

Interventions

• Device Superabsorbent dressing application
  Cutimed Sorbion or Zetuvit plus (RespoSorb) application to maintain wound exudate

Primary outcome measures

• Exudate management performance [Time frame: up to 30 days]

Secondary outcome measures (8)

• Dressing change frequency [Time frame: up to 30 days]
• Moisture-associated skin damages [Time frame: up to 30 days]
• Occurrence clinical relevant peri-wound skin changes [Time frame: up to 30 days]
• Changes in wound tissue and general wound pain [Time frame: up to 30 days]
• Need for debridement after product removal [Time frame: up to 30 days]
• Patient satisfaction with treatment and product [Time frame: final study visit]
• HCP satisfaction with treatment and product [Time frame: final study visit]
• Changes in quality of life using the "Wound-QoL 14" (short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments) [Time frame: day 0 and day 30]

Eligibility criteria

Inclusion criteria

• Participant is informed about the trial, understands the nature of the study and provides written informed consent prior to study enrolment
• Participant is mentally and physically able to participate in this study
• Men, women, diverse ≥ 18 years
• Participant complies with study visit schedule
• Participant agrees to comply with all standard therapies (e.g., with regards to compression therapy)
• Participant suffers from lower leg ulcer\* (including the ankle but not the feet) indicated to be treated with the study deviceinvestigational devices, requiring compression and fulfilling the following:
• Ulcer is not younger than 4 weeks and not older than 1 year
• Ulcer is ranging between 2 cm2 and 800 cm2
• One side of the ulcer is not extending 40 cm
• Depth of ulcer < 2 cm
• Ankle-brachial pressure index (ABPI) of >0.8 and ≤1.3, measurement not older than 12 months \* Participants with more than one ulcer are eligible for inclusion, however only one ulcer per patient will be included in the study.

Exclusion criteria

• Participant already participates in this study with one ulcer (only one ulcer per participant is allowed)
• Participant is expected not to be willing or able to follow the study outlines and requirements
• Participant suffers from systemic infectious disease(s) known to negatively influence wound healing, such as AIDS
• Participant is undergoing an immuno-compromising therapy, such as systemic antineoplastic drugs and/or systemic corticosteroids
• Participant uses any medication that could potentially delay the wound healing ability
• Participant is an employee (staff or student) of the hospital site (institute) or the sponsor or is in a dependent relationship with a member of site or sponsor staff, e.g. child, spouse etc.
• Participant is pregnant or currently breastfeeding
• Participant reporting (and/or suspected by investigator) addiction from alcohol or drugs or is substituted e.g., by Methadone

8\. Participant suffers from alcohol or drug addiction or is substituted e.g., by Methadone 9. Participant is or has been included in another clinical investigation with medical devices or pharmaceutical drugs at present or during the past 30 days 10. Participant with a history of sensitivity to any of the components of the study product 11. Participant whose leg ulcers are clinically infected (e.g., erysipelas) or malignant 12. Study ulcer requiring negative pressure wound therapy or hyperbaric oxygen during the trial 13. The ulcer has exposed bone, tendon, ligaments and/or joint 14. History of radiation at the study ulcer site 15. Participant's lesion is a primary skin cancer 16. Participant's lesion is the manifestation of a metastasis

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Single blind

Primary purpose

Treatment

Study locations

United Kingdom · 2 centers

• Mid Yorkshire Teaching NHS Trust Pinderfields Hospital — Wakefield
• Northumbria Healthcare NHS Foundation Trust — Ashington

Germany · 1 center

• Niels Stensen Klinik, Christliches-Klinikum-Melle — Melle

Identifiers

NCT: NCT06300762 · C3079

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗